Market Place
Sourcing Support
All News #Library
Biotech
LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab
30 Mar 2026 //
BUSINESSWIRE
LEO Pharma SPEVIGO Shows Long-Term Data In GPP At AAD 2026
27 Mar 2026 //
BUSINESSWIRE
LEO Pharma Closes Deal for Spevigo
01 Oct 2025 //
BUSINESSWIRE
LEO Pharma: Week 16 Tralokinumab Data Predicts Long-Term Response
19 Sep 2025 //
BUSINESSWIRE
LEO Pharma`s Tralokinumab Shows Positive 16-Week Results in Trial
09 Jul 2025 //
BUSINESSWIRE
Junshi Partners With LEO Pharma For Toripalimab In Europe
21 Jan 2025 //
GLOBENEWSWIRE
Gilead, LEO Pharma to programs for inflammatory diseases
13 Jan 2025 //
REUTERS
LEO Pharma Presents ECZTEND Trial Results for Adbry® in AD
25 Oct 2024 //
BUSINESSWIRE
LEO Pharma Presents Adbry® and Delgocitinib Data at Conference
23 Oct 2024 //
BUSINESSWIRE
LEO Pharma Presents Tralokinumab Data At EADV 2024 For AD
27 Sep 2024 //
BUSINESSWIRE
LEO Presents Extensive Data of 5 Late Breaking Abstracts At EADV
25 Sep 2024 //
BUSINESSWIRE
LEO Pharma Presents Anzupgo® Data At EADV 2024
25 Sep 2024 //
BUSINESSWIRE
Adbry Autoinjector Available For Moderate-To-Severe Atopic Dermatitis Treatment
17 Sep 2024 //
BUSINESSWIRE
LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data
08 Mar 2024 //
BUSINESSWIRE
LEO Pharma Presents Positive Phase 2a Efficacy Results of LEO 138559
18 Mar 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.